This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Gilead (GILD) Q3 Earnings & Sales Top, Guidance Raised
by Zacks Equity Research
Gilead (GILD) Q3 earnings and sales beat on strong HIV and oncology business. The company also raises its annual guidance.
Amarin (AMRN) Q3 Earnings Beat, Sales Hurt by Vascepa Generics
by Zacks Equity Research
Amarin's (AMRN) Vascepa sales decline year over year amid rising generic competition and the restructuring initiatives in the third quarter. The stock witnesses a decline on Oct 27.
Bristol-Myers (BMY) Q3 Earnings Beat, Sales Decline Y/Y
by Zacks Equity Research
Bristol-Myers' (BMY) third-quarter 2022 earnings beat estimates while sales miss the same due to a decline in sales of Revlimid.
Novartis (NVS) Q3 Earnings Top, Revenues Miss Estimates
by Zacks Equity Research
Novartis (NVS) reports mixed results for the third quarter as key brands maintain momentum but generic competition remains a drag.
Roche (RHHBY) Q3 Revenues Dip on Lower COVID-19-Related Sales
by Zacks Equity Research
Roche's (RHHBY) performance in the third quarter was pretty ho-hum as COVID-19-related sales continue to decline.
Novartis' (NVS) Pluvicto Secures Positive CHMP Opinion
by Zacks Equity Research
Novartis (NVS) radioligand therapy Pluvicto gets positive recommendation by the CHMP for patients with progressive, PSMA-positive metastatic castration-resistant prostate cancer.
Puma Biotech (PBYI) Inks Agreement for Takeda's Alisertib
by Zacks Equity Research
Puma Biotechnology (PBYI) inks license agreement with Japan's Takeda Pharmaceuticals, gaining worldwide development and commercialization rights to the latter's cancer treatment alisertib.
Puma Biotech's (PBYI) Nerlynx Aids Top Line, Overdependence a Woe
by Zacks Equity Research
Puma Biotech (PBYI) has only one marketed product in its portfolio, Nerlynx, for HER-2 positive breast cancer patients. It continues to evaluate Nerlynx in other types of cancer and indications.
Puma Biotech (PBYI) Stock up as Q2 Earnings & Sales Beat
by Zacks Equity Research
Puma Biotech (PBYI) beats earnings and revenue estimates in second-quarter 2022. PBYI's stock surges at market close following the news.
Puma Biotech (PBYI) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Puma Biotech (PBYI) delivered earnings and revenue surprises of 950% and 11.84%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Celldex (CLDX) Surges 9%: Is This an Indication of Further Gains?
by Zacks Equity Research
Celldex (CLDX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Why Is Reata Pharmaceuticals, Inc. (RETA) Up 53.1% Since Last Earnings Report?
by Zacks Equity Research
Reata Pharmaceuticals, Inc. (RETA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Puma Biotech (PBYI) Q1 Earnings Beat, Nerlynx Sales Fall Y/Y
by Zacks Equity Research
Puma Biotech (PBYI) Q1 loss narrows while sales come in line with estimates. PBYI's stock declines in the after-market trading session following the news.
Puma Biotech (PBYI) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Puma Biotech (PBYI) delivered earnings and revenue surprises of 38.46% and 0.78%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Voyager Therapeutics (VYGR) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of -300% and 97.67%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Puma Biotech (PBYI) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Puma Biotech (PBYI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Puma Biotech (PBYI) Q4 Earnings Beat Mark, Revenues Rise Y/Y
by Zacks Equity Research
Puma Biotechnology (PBYI) beats on earnings and sales for the fourth quarter of 2021. PBYI???s shares increase in after-market trading session following the news.
Puma Biotech (PBYI) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Puma Biotech (PBYI) delivered earnings and revenue surprises of 190.91% and 16.14%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Puma Biotech (PBYI) Report Negative Q4 Earnings? What You Should Know
by Zacks Equity Research
Puma Biotech (PBYI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Nurix Therapeutics, Inc. (NRIX) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Nurix Therapeutics, Inc. (NRIX) delivered earnings and revenue surprises of -26.87% and 50.67%, respectively, for the quarter ended November 2021. Do the numbers hold clues to what lies ahead for the stock?
Do Options Traders Know Something About Puma (PBYI) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Puma (PBYI) stock based on the movements in the options market lately.
Puma (PBYI) Misses on Q3 Earnings, Cuts Sales View, Stock Down
by Zacks Equity Research
Puma Biotech (PBYI) reports lower-than-expected Q3 earnings and sales. It slashes 2021 Nerlynx sales guidance.
Puma Biotech (PBYI) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Puma Biotech (PBYI) delivered earnings and revenue surprises of -373.91% and -13.59%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Puma Biotech (PBYI) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Puma Biotech (PBYI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Puma (PBYI) Q2 Loss Narrower Than Expected, Nerlynx View Cut
by Zacks Equity Research
Puma Biotech (PBYI) reports better-than-expected Q2 earnings and sales. It lowers 2021 Nerlynx sales guidance.